Dosificación dinámica de enoxaparina en paciente crítico con aumento del aclaramiento renal

Monsalve Naharro, José Ángel; Pardo, Manuel Gerónimo; Moreno Flores, Beatriz; Domingo Chiva, Esther; Cuesta Montero, Pablo; Díaz Rangel, Marca; Ortega Cerrato, Agustín.
Rev. nefrol. diál. traspl ; 37(3): 167-171, sept. 2017. graf
Artículo en Español | LILACS | ID: biblio-1006530

Documentos relacionados

  1. Non-weight-based enoxaparin dosing subtherapeutic in trauma patients.
  2. IV enoxaparin in pediatric and cardiac ICU patients.
  3. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children.
  4. Population Pharmacokinetics of Enoxaparin in Pediatric Patients.
  5. Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.
  6. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.
  7. Letter by Martin et al Regarding Article, "Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial".
  8. Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD.
  9. Characterization of an andexanet alfa administration protocol guided by drug-specific quantitative anti-Xa assays.
  10. Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients.